Comparative Pharmacology
Head-to-head clinical analysis: IMODIUM MULTI SYMPTOM RELIEF versus LOMANATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMODIUM MULTI SYMPTOM RELIEF versus LOMANATE.
IMODIUM MULTI-SYMPTOM RELIEF vs LOMANATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loperamide binds to mu-opioid receptors in the intestinal wall, reducing peristalsis and increasing intestinal transit time, thereby allowing for greater absorption of water and electrolytes. Simethicone reduces surface tension of gas bubbles, facilitating their coalescence and expulsion.
LOMANATE is a combination of diphenoxylate (a peripheral opioid receptor agonist that slows GI motility) and atropine (an anticholinergic that discourages abuse).
4 mg orally initially, then 2 mg after each unformed stool; maximum 8 mg/day for OTC use (prescription up to 16 mg/day). Route: oral.
100 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life is approximately 9-14 hours (mean 11 hours) in plasma; in clinical context, it supports twice-daily dosing for chronic diarrhea.
Terminal elimination half-life is 18-24 hours in adults with normal renal function; prolonged to 40-60 hours in severe renal impairment (CrCl < 30 mL/min), requiring dose adjustment.
Fecal: ~60% (loperamide and metabolites); Renal: ~1-2% (unchanged loperamide and glucuronide conjugates); Biliary: minimal, as loperamide undergoes extensive enterohepatic recirculation.
Primarily renal (80% as unchanged drug and metabolites); biliary/fecal (15%); 5% eliminated via other routes.
Category C
Category C
Antidiarrheal
Antidiarrheal